VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005645/en/
"Thales Alenia Space". Copyright: Thales
Global recognition for research and innovation
The Derwent Top 100 Global Innovators ranking recognises the volume, success and influence of the patents filed by technology companies. Thales has appeared six times in this prestigious ranking, reflecting the company’s commitment to innovating, bringing inventions to market and protecting its ideas.
This distinction comes at a turning point in Thales’s history. With the completion of the acquisition of Gemalto on 2 April, the Group now employs 28,000 engineers, devotes €1 billion a year to self-funded R&D and maintains a portfolio of 20,500 patents, including 400 filed in 2018. At the show, Thales will also sign the LGBT+ Charter championed by Autre Cercle, thus highlighting the group’s strategy of promoting diversity and inclusion across its talent pool, as a way to free creative potential and foster innovation.
Thales at VivaTech: AI for every decisive moment
Thales will be showcasing its latest innovations alongside some 30 start-ups from six countries specialising in artificial intelligence, connectivity, drone technology, cybersecurity and robotics.
A series of demonstrations will show how advanced technology helps real-life users to understand the most complex situations:
- Columbus invites visitors to feel what it’s like to be an astronaut on-board the International Space Station’s science laboratory.
- The autonomous train demonstrator lets visitors drive a New York City subway train and see how they match up to the capabilities of artificial intelligence.
- Piume allows users to experience what it’s like to be an explorer or a researcher working in harsh environments.
- Geonav uses the Galileo satellite constellation to prevent risks faced by high-level athletes, without the dropped signals that often occur inside sports stadiums.
- Smart New World combines the power of holographic displays with IoT (Internet of Things) technology.
- The 3D interactive hologram table developed with the Australian start up Euclideon models anything you can imagine: cities, objects, design techniques and much more.
Thales experts will also be taking part in around 40 panel sessions to discuss how artificial intelligence that is trustable, explainable and certifiable can be used to invent or reinvent the cities of the future, develop autonomous trains and future medical imaging solutions, protect the environment and take space exploration to the next frontier. The schedule for the demonstrations and panel sessions can be found on the Thales event website.
Thales Decisive Journeys at VivaTech
- DecisiveJourney#1: From space observation to personal data protection: find out how trusted AI is a decisive technology for Thales
- DecisiveJourney#2: Thales technologies applied to environmental protection
- DecisiveJourney#3: Artificial nano-neurons and medical imaging: Thales innovations reshaping the future of medicine
- DecisiveJourney#4: How to develop responsible AI
- DecisiveJourney#5: How digital is changing our companies and work methods
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018
PLEASE VISIT
Thales
Group
Twitter: @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005645/en/
Contact information
Thales, Media Relations
Alice Pruvot +33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom